Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?

Citius Pharmaceuticals (NASDAQ:CTXR) stock is on the rise Tuesday after the company announced new results from its Phase 3 clinical trial of Mino-Lok. Mino-Lok is Citius Pharmaceuticals' antibiotic lock solution for patients with central line-associated infections or catheter-related bloodstream infections. The good news for CTXR investors is that this trail met both its primary and secondary endpoints. The primary endpoint was extending the time until catheter failure. In the control arm, the median failur ...